Related references
Note: Only part of the references are listed.Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies
Paola Fioretto et al.
DRUGS & AGING (2016)
Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial
Wenying Yang et al.
JOURNAL OF DIABETES (2016)
Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes
C. David Sjostrom et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus
E. Araki et al.
DIABETES OBESITY & METABOLISM (2015)
Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels
C. D. Sjostrom et al.
DIABETES OBESITY & METABOLISM (2015)
Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function
Aurora Merovci et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Ethnic/Race Diversity and Diabetic Kidney Disease
Vasantha Muthu Muthuppalaniappan et al.
JOURNAL OF CLINICAL MEDICINE (2015)
Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study
A. Kashiwagi et al.
DIABETES OBESITY & METABOLISM (2015)
Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea
L. Ji et al.
DIABETES OBESITY & METABOLISM (2015)
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
Kohei Kaku et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study
Linong Ji et al.
CLINICAL THERAPEUTICS (2014)
Body Composition Is the Main Determinant for the Difference in Type 2 Diabetes Pathophysiology Between Japanese and Caucasians
Jonas B. Moller et al.
DIABETES CARE (2014)
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin
M. A. Nauck et al.
DIABETES OBESITY & METABOLISM (2014)
Efficacy and safety of dapaglflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise
K. Kaku et al.
DIABETES OBESITY & METABOLISM (2014)
Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria
Suzanne Geerlings et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events
Agata Ptaszynska et al.
DRUG SAFETY (2014)
Ethnic Differences in Insulin Sensitivity, β-Cell Function, and Hepatic Extraction Between Japanese and Caucasians: A Minimal Model Analysis
Jonas B. Moller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
BMI and waist circumference are associated with impaired glucose metabolism and type 2 diabetes in normal weight Chinese adults
Shengxu Li et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2014)
The Architecture of Risk for Type 2 Diabetes: Understanding Asia in the Context of Global Findings
Noraidatulakma Abdullah et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2014)
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Michael A. Nauck
DRUG DESIGN DEVELOPMENT AND THERAPY (2014)
Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial
Krzysztof Strojek et al.
DIABETES THERAPY (2014)
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
Clifford J. Bailey et al.
BMC MEDICINE (2013)
Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects
Li Yang et al.
CLINICAL THERAPEUTICS (2013)
Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial
K. Kaku et al.
DIABETES OBESITY & METABOLISM (2013)
Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
Scott C. Thomson et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2012)
Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial
John P. H. Wilding et al.
ANNALS OF INTERNAL MEDICINE (2012)
Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
Julio Rosenstock et al.
DIABETES CARE (2012)
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
R. R. Henry et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
Deriving Ethnic-Specific BMI Cutoff Points for Assessing Diabetes Risk
Maria Chiu et al.
DIABETES CARE (2011)
Globalization of Diabetes The role of diet, lifestyle, and genes
Frank B. Hu
DIABETES CARE (2011)
Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus
S. Kasichayanula et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
K. Strojek et al.
DIABETES OBESITY & METABOLISM (2011)
Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
James F. List et al.
KIDNEY INTERNATIONAL (2011)
Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS)
Susanne Tan et al.
BMC MEDICAL GENETICS (2010)
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
Ele Ferrannini et al.
DIABETES CARE (2010)
Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Diabetes in Asia Epidemiology, Risk Factors, and Pathophysiology
Juliana C. N. Chan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT)
Scott A. Lear et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2007)
Epidemic obesity and type 2 diabetes in Asia
Kun-Ho Yoon et al.
LANCET (2006)
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies
C Barba et al.
LANCET (2004)
Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes
M Fukushima et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2004)
Share Paper
